BridgeBio to Present Additional Data from Phase 3 FORTIFY Trial at MDA Conference

The biopharmaceutical company will share interim analysis results and other advances in understanding limb-girdle muscular dystrophy type 2I/R9.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

BridgeBio Pharma announced that additional data from the interim analysis of the Phase 3 FORTIFY clinical trial of its investigational therapy BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) will be presented at the upcoming MDA Clinical & Scientific Conference. The company will also share findings from its academic collaborators at Yale School of Medicine, along with four posters highlighting advances in understanding BBP-418 and LGMD2I/R9.

Why it matters

LGMD2I/R9 is a rare genetic condition that causes progressive muscle weakness, and patients currently have limited treatment options. The data from the FORTIFY trial could provide important insights into a potential new therapy, while the additional research presentations aim to further the scientific understanding of this debilitating disease.

The details

The late-breaking oral presentation will feature the interim analysis results from the ongoing Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9 patients. An oral presentation from BridgeBio's collaborators at Yale will focus on a high-throughput assay for measuring ribitol response across FKRP gene variants. Four posters will cover topics including a systematic literature review of clinical outcomes and disease burden, real-world insights into LGMD treatment patterns and costs, and long-term health and economic modeling for LGMD2I/R9.

  • The MDA Clinical & Scientific Conference will take place from March 8-11, 2026 in Orlando, Florida.
  • The late-breaking oral presentation on the FORTIFY interim analysis results is scheduled for Wednesday, March 11 at 2:00 pm ET.
  • The oral presentation from the Yale collaborators is set for Wednesday, March 11 at 11:30 am ET.
  • The four posters will be presented on Tuesday, March 10.

The players

BridgeBio Pharma, Inc.

A biopharmaceutical company focused on developing medicines for genetic conditions.

Katherine Mathews, M.D.

Professor of Pediatrics and Neurology at the University of Iowa's Roy J. and Lucille A. Carver College of Medicine.

Yujiao Yang, Ph.D.

Postdoctoral Associate in the Laboratory of Monkol Lek at Yale School of Medicine.

LGMD2I/R9

Limb-girdle muscular dystrophy type 2I/R9, a rare genetic condition that causes progressive muscle weakness.

BBP-418

BridgeBio's investigational therapy for the treatment of LGMD2I/R9.

Got photos? Submit your photos here. ›

What they’re saying

“Interim Analysis from Ongoing Phase 3 FORTIFY Study of BBP-418 for Patients with LGMD2I/R9 Meets Efficacy Endpoints”

— Katherine Mathews, M.D., Professor of Pediatrics and Neurology (MDA Clinical & Scientific Conference)

“A High-Throughput Assay for Measuring Ribitol Response Across FKRP Variants”

— Yujiao Yang, Ph.D., Postdoctoral Associate (MDA Clinical & Scientific Conference)

The takeaway

The upcoming presentations at the MDA Clinical & Scientific Conference highlight BridgeBio's progress in developing a potential new therapy for the rare and debilitating LGMD2I/R9 condition, as well as broader advancements in understanding the underlying genetics and disease burden. These findings could help advance much-needed treatment options for patients living with this genetic disorder.